Loading patent…
AssigneeResearch Corporation Technologies, Inc.
InventorsKurt R. Gehlsen, Timothy David Jones, Francis Joseph Carr, Arron Hearn
Estimating the term…
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
A modified sarcin polypeptide comprising at least one mutation as compared to a wild type α-sarcin polypeptide (SEQ ID NO:1), wherein the at least one mutation is within a first T cell epitope and/or a second T cell epitope of the wild type α-sarcin polypeptide, wherein the first T cell epitope consists of the amino acid sequence XKNPKTNKY (SEQ ID NO:44), wherein X is Q or DQ and the second T cell epitope consists of the amino acid sequence IIAHTKENQ (SEQ ID NO:4).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.